Knowing that HIV prevention exists is not the same as knowing which option fits someone’s life. That’s why helping patients understand their PrEP options is becoming just as important as raising awareness. ViiV Healthcare’s PrEP Wisdom campaign asks people to look beyond injection schedules and consider what different prevention methods involve. For pharmaceutical marketers, it signals a shift: when choices multiply, awareness alone cannot prepare people to make them. Can an unbranded campaign help patients compare options without quietly steering them toward its sponsor’s product?
Table of Contents
- Why PrEP Marketing Must Move Beyond Basic Awareness
- What Real PrEP Choices Look Like Beyond Dosing
- Where Disease Education Can Become Product Advertising
- How Marketers Should Measure Better Patient Decisions
- Conclusion
- FAQ
Why PrEP Marketing Must Move Beyond Basic Awareness
For years, HIV prevention campaigns had a basic task: explain that pre-exposure prophylaxis, or PrEP, exists. However, the market has changed. Daily oral options, including Truvada and Descovy, now share attention with long-acting injections. ViiV’s Apretude follows an injection schedule that continues every two months after initiation. Meanwhile, Gilead’s Yeztugo, approved in 2025, uses injections every six months. These schedules offer choices, but they do not tell the full story.
ViiV launched PrEP Wisdom in June 2026 with Michelle Visage, then added actor Jeremy Pope in November. Rather than naming a preferred medicine, the campaign encourages questions about injectable differences. Its message addresses a growing challenge: patients may know longer-acting prevention is available yet have little idea what to discuss at an appointment.
Moreover, competing drugmakers have incentives to make their own advantages memorable. The result is a category where information is plentiful, but decision confidence may be limited. For marketers, PrEP decision education is about helping people compare their options rather than simply recognizing that prevention exists.
What Real PrEP Choices Look Like Beyond Dosing
An injection every six months may sound simpler than one every two months. Yet convenience depends on more than a calendar. Patients may want to know where a medicine is injected, how treatment begins, and whether injection-site reactions could disrupt daily life. They should also ask about other medications, HIV testing, missed appointments, and stopping PrEP. Cost, insurance coverage, and clinic access matter, too.
These questions should lead to balanced conversations, not a ranked list of winners. For example, Apretude contains cabotegravir, while Yeztugo contains lenacapavir. They are different medicines with distinct administration instructions and safety considerations.
The CDC’s clinical guidance for lenacapavir highlights the importance of appropriate testing, medication interactions, and follow-up care. However, available evidence does not establish that either injectable is best for everyone. In addition, oral PrEP remains a valid choice for many people.
Strong patient education explains these differences in plain language and encourages questions about personal preferences. A shorter dosing schedule may appeal to one person, while another may prefer a familiar daily routine. Neither preference should replace a medical assessment.
Ultimately, patients and clinicians need to weigh health history, treatment requirements, and practical concerns together. People seeking individual guidance can find healthcare professionals through Healthcare.pro.
Where Disease Education Can Become Product Advertising
The harder marketing question is who controls the comparison. ViiV sells Apretude, so education about injectable differences also operates in a competitive market. That does not make the information misleading. However, it raises the bar for transparency and thoughtful creative review.
Disease awareness materials should help people understand a health issue without implying that the sponsor’s medicine is the obvious answer. The distinction becomes especially important when a campaign highlights differences that may also support a brand’s competitive positioning.
The FDA distinguishes disease awareness communications from prescription drug promotion. Its research on disease awareness and prescription drug advertising also shows that consumers can confuse general health messages with claims about specific medicines.
Consequently, marketers must test not only what individual claims say, but what audiences understand from the overall message. Are competing options described fairly? Can patients recognize relevant risks and practical burdens? Does the call to action encourage clinician discussion instead of a predetermined prescription?
As Pharma Marketing Network has noted in its coverage of FDA promotional review, the overall impression of an advertisement can create regulatory concerns even when individual statements appear defensible.
For brands investing in patient education, the challenge is to communicate meaningful differences without turning a disease awareness campaign into disguised product-selection advertising. That requires medical, legal, and regulatory teams to consider the entire patient experience, not just the wording of individual messages.
How Marketers Should Measure Better Patient Decisions
Traditional pharmaceutical marketing dashboards favor reach, video views, search volume, and clicks. Those metrics show attention, but they cannot prove that people understand their choices. Instead, marketers should measure how well patients understand their prevention options and whether they feel prepared to ask informed questions.
For example, surveys could test whether audiences recognize differences in administration, drug interactions, follow-up requirements, and access. Follow-up research might also assess readiness to discuss PrEP with a clinician without naming a preferred brand.
Importantly, marketers should not treat growth in one product’s prescriptions as the only sign of success. An informed patient could choose an oral option, a competing injection, or more time to decide. That can still represent a valuable educational outcome.
Pharma Marketing Network’s coverage of competitive direct-to-consumer advertising illustrates why campaigns may expand an entire treatment category rather than benefiting only the sponsor’s product.
Digital healthcare advertising partners such as eHealthcare Solutions can help distribute educational content to relevant audiences. However, effective targeting cannot replace accurate, balanced messaging.
The stronger measure is whether patients leave a campaign better prepared to participate in a medically appropriate decision. When marketers focus on understanding rather than exposure alone, education becomes a more meaningful part of the patient journey.
Conclusion
PrEP Wisdom reflects a wider change in pharmaceutical marketing. Awareness opens the door, but meaningful education helps people understand what comes next. As prevention options become more varied, marketers have an opportunity to explain practical differences without disguising product promotion as neutral advice.
Ultimately, effective PrEP education helps patients approach healthcare conversations with clearer questions, greater confidence, and a better understanding of their choices. For pharmaceutical marketers, that is a more useful goal than awareness alone.
FAQ
How does patient education help people choose a PrEP option?
Patient education helps people understand available HIV prevention methods, compare practical differences, and prepare useful questions for healthcare professionals. It supports informed discussions rather than directing everyone toward the same medicine.
Is PrEP Wisdom a branded drug campaign?
PrEP Wisdom is a ViiV-sponsored education campaign that does not directly name Apretude in its main messaging. However, marketers must consider whether the overall impression suggests a particular product or creates an unintended promotional message.
Are all injectable PrEP options alike?
No. Injectable PrEP options can differ in dosing schedules, administration methods, side effects, drug interactions, and follow-up requirements. A healthcare professional can explain which differences are medically relevant to an individual’s needs.
Why is informed patient choice important for pharmaceutical marketing?
As treatment and prevention categories grow, awareness alone becomes less useful. Helping patients understand meaningful differences can support better healthcare conversations, stronger trust, and more informed decisions.
How can pharmaceutical marketers measure patient understanding?
Marketers can evaluate comprehension of treatment differences, confidence in asking questions, and readiness for clinical conversations. These measures provide useful context alongside traditional engagement metrics such as clicks, views, and website visits.
This content is not medical advice. For any health issues, always consult a healthcare professional. In an emergency, call 911 or your local emergency services.












